ripekg:evaluation/RIPEA44B073B6366CEDA7 |
prov:used |
ripekg:registry-evidence/RIPEA44B073B6366CEDA7 |
ripekg:registry-evidence/RIPEA44B073B6366CEDA7 |
rdf:type |
rdfs:Resource |
ripekg:registry-evidence/RIPEA44B073B6366CEDA7 |
rdf:type |
owl:Thing |
ripekg:registry-evidence/RIPEA44B073B6366CEDA7 |
rdf:type |
ripe:IntegrityAssessmentEvidenceIntegrity assessment evidence |
ripekg:registry-evidence/RIPEA44B073B6366CEDA7 |
rdf:type |
ripe:RegistryEvidenceRegistry evidence |
ripekg:registry-evidence/RIPEA44B073B6366CEDA7 |
rdf:type |
tido:Evidence |
ripekg:registry-evidence/RIPEA44B073B6366CEDA7 |
prov:wasAttributedTo |
ripekg:source/clinicaltrials-govClinicalTrials.gov |
ripekg:registry-evidence/RIPEA44B073B6366CEDA7 |
prov:wasGeneratedBy |
ripekg:evidence-aggregation/RIPEA44B073B6366CEDA7 |
ripekg:registry-evidence/RIPEA44B073B6366CEDA7 |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA44B073B6366CEDA7 |
ripekg:registry-evidence/RIPEA44B073B6366CEDA7 |
ripe:concerns |
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study |
ripekg:registry-evidence/RIPEA44B073B6366CEDA7 |
ripe:isProspective |
false |
ripekg:registry-evidence/RIPEA44B073B6366CEDA7 |
ripe:registrationAssessmentRationale |
Registration date is after LLM recruitment start date. |
ripekg:registry-evidence/RIPEA44B073B6366CEDA7 |
ripe:registrationDate |
12-04-2016 |
ripekg:registry-evidence/RIPEA44B073B6366CEDA7 |
ripe:registrationId |
NCT02739568 |
ripekg:registry-evidence/RIPEA44B073B6366CEDA7 |
ripe:registrationLink |
https://clinicaltrials.gov/study/NCT02739568 |
ripekg:registry-evidence/RIPEA44B073B6366CEDA7 |
ripe:registryName |
ClinicalTrials.gov |
ripekg:registry-evidence/RIPEA44B073B6366CEDA7 |
tido:supports |
ripekg:integrity-assessment-hypothesis/RIPEA44B073B6366CEDA7-human-2-2 |
ripekg:registry-evidence/RIPEA44B073B6366CEDA7 |
tido:supports |
ripekg:integrity-assessment-hypothesis/RIPEA44B073B6366CEDA7-inspectai-2-2 |